Loading organization details...
Loading organization details...
Source: IRS Form 990 via ProPublica Nonprofit Explorer
Total Revenue
▼$95.2K
Total Contributions
N/A
Total Expenses
▼$78.4K
Total Assets
$25.4K
Total Liabilities
▼$0
Net Assets
N/A
Officer Compensation
→N/A
Other Salaries
N/A
Investment Income
▼N/A
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$7.5M
Awards Found
10
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Labor | YOUTH BUILD | $1.5M | FY2020 | Jan 2020 – Apr 2024 |
| Department of Labor | SEE NOTICE OF AWARD, ATTACHMENT 1 - TERMS AND CONDITIONS, ATTACHMENT D-STATEMENT OF WORK, ABSTRACT | $1.4M | FY2025 | Feb 2025 – May 2028 |
| Department of Labor | YOUTH BUILD | $1.1M | FY2022 | May 2022 – Sep 2025 |
| Department of Labor | YOUTH BUILD | $1.1M | FY2017 | Sep 2017 – Dec 2020 |
| Department of Labor | YOUTH BUILD | $1.1M | FY2011 | Jun 2011 – May 2014 |
| Department of Labor | YOUTH BUILD | $756K | FY2009 | Jul 2009 – Jun 2012 |
| Department of Health and Human Services | SELECTIVE ANTIMICROBIAL PEPTIDES FROM MILK FOR BACTERIAL VAGINOSIS - PROJECT ABSTRACT SEVERAL CURRENTLY ADMINISTERED ANTIBIOTICS RAISE TWO MAIN CONCERNS: RESISTANCE AND NON-SELECTIVITY. THE RAPID RATE OF EMERGING MULTI-DRUG RESISTANCE POSES A GLOBAL HEALTH THREAT AND DRAMATICALLY INCREASES ECONOMIC BURDEN. WITH TRADITIONAL ANTIBIOTICS BEING LARGELY NON-SELECTIVE, THERE ARE SERIOUS SIDE EFFECTS DUE TO THE NATURAL HOST MICROBIOME BEING MODIFIED, AND THUS A LOSS IN HOMEOSTASIS. THE STRONG NEED FOR INNOVATIVE, POTENT, NATURALLY OCCURRING AND SPECIFICALLY SELECTIVE THERAPEUTICS HAVE PROMPTED US TO EXPLORE FOR SUCH BIOACTIVE MOLECULES IN MILK. THE RESULT OF 200 MILLION YEARS OF EVOLUTIONARY PRESSURE, MAMMALIAN LACTATION GUIDES THE DEVELOPMENT OF THE INFANT AND PROVIDES PROTECTION FROM A WIDE-VARIETY OF INFECTIONS. UPON FRACTIONATING THOUSANDS OF NATURALLY OCCURRING PEPTIDES FROM HUMAN MILK, AND DISCOVERING THEIR ANTIBACTERIAL ACTIVITY, WE HAVE FOCUSED ON THE FUNCTION AND MECHANISM OF ACTION OF NOVEL ANTIMICROBIAL PEPTIDES FROM HUMAN MILK. ONE SUCH PEPTIDE, HBCA2, AN INTERNAL 12-MER SEQUENCE OF HUMAN B-CASEIN RAPIDLY ELIMINATES THE VIABILITY OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA, INCLUDING BUT NOT LIMITED TO CATEGORY 1 PRIORITY PATHOGENS. WE HAVE MADE THE KEY OBSERVATION THAT GARDNERELLA VAGINALIS, A MAJOR BACTERIAL VAGINOSIS (BV)-ASSOCIATED PATHOGEN, IS SUSCEPTIBLE TO HBCA2, WHEREAS THE VIABILITY OF KEY LACTOBACILLI LINKED TO A HEALTHY VAGINAL MICROBIOME REMAINS UNALTERED. BV REMAINS AN UNMET NEED, WITH FEW TREATMENT OPTIONS AND HIGH RATES OF RECURRENCE RESULTING IN SEVERAL PUBLIC HEALTH CONCERNS FOR WOMEN OF REPRODUCTIVE AGE. IT IS ASSOCIATED WITH OUTCOMES INCLUDING TO NOT LIMITED TO PRE-TERM LABOR, STI AND HIV TRANSMISSIONS, AND OTHER REPRODUCTIVE CHALLENGES. WE PROPOSE HBCA2, A MILK-BORNE, ANTIMICROBIAL PEPTIDE, WITH ITS UNIQUE SELECTIVITY FEATURE OF INERTNESS TOWARDS COMMENSAL BACTERIA, AS A LEAD CANDIDATE MOLECULE IN TOPICAL APPLICATIONS FOR THE TREATMENT OF BV—A THERAPY THAT COULD IN TURN REDUCE THE BURDEN OF BV OUTCOMES. IN THIS PHASE I SBIR GRANT, WE WILL EVALUATE A LARGER RANGE OF G. VAGINALIS STRAINS OTHER BACTERIAL VAGINOSIS ASSOCIATED BACTERIA AS WELL AS A LARGER NUMBER OF VAGINAL AND PROBIOTIC LACTOBACILLI FOR THEIR RESPONSE TO HBCA2 AND VARIANTS OF HBCA2 SYNTHESIZED TO ENHANCE EFFICACY. ADDITIONALLY, WE WILL DETERMINE THE HBCA2 MECHANISM OF ACTION, EXAMINE ITS EFFICACY AND/OR SYNERGY TO TRADITIONAL ANTIMICROBIALS, CHARACTERIZE RESISTANCE MUTATIONS (IF ANY), ANALYZE THE DIRECT EFFECT OF HBCA2 ON MAMMALIAN HOST CELLS AND DETERMINE THE IMPACT OF FUNCTION ON INFECTION AND INFLAMMATION IN PRE- CLINICAL INFECTION MODELS OF THE FEMALE REPRODUCTIVE TRACT. THIS WORK WILL AID THE PREPARATION FOR PHASE II, WHERE WE WILL TEST HBCA2 IN IN VIVO EFFICACY AND EARLY SAFETY PK STUDIES, AND DETERMINE CERVICOVAGINAL TISSUE IMPACT AND IMMUNE RESPONSE. ULTIMATELY, THIS PROPOSAL WILL ALLOW US TO FURTHER CHARACTERIZE HBCA2 ALONE OR IN COMBINATION WITH ADDITIONAL SUCH PEPTIDES AS POTENT ANTIBACTERIAL THERAPEUTIC, DERIVED FROM MILK, WHICH CAN BE EMPLOYED FOR TREATMENT OF RECURRENT BV VIA TOPICAL APPLICATIONS. | $287K | FY2022 | May 2022 – Mar 2024 |
| Department of Agriculture | RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS | $150K | FY2015 | Sep 2015 – Sep 2015 |
| Department of Agriculture | DOMESTIC WATER GRANTS - REGULAR | $100K | FY2010 | Jun 2010 – Jun 2010 |
| Department of Housing and Urban Development | YOUTHBUILD | $4,626 | FY2005 | Oct 2004 – Sep 2009 |
Department of Labor
$1.5M
YOUTH BUILD
Department of Labor
$1.4M
SEE NOTICE OF AWARD, ATTACHMENT 1 - TERMS AND CONDITIONS, ATTACHMENT D-STATEMENT OF WORK, ABSTRACT
Department of Labor
$1.1M
YOUTH BUILD
Department of Labor
$1.1M
YOUTH BUILD
Department of Labor
$1.1M
YOUTH BUILD
Department of Labor
$756K
YOUTH BUILD
Department of Health and Human Services
$287K
SELECTIVE ANTIMICROBIAL PEPTIDES FROM MILK FOR BACTERIAL VAGINOSIS - PROJECT ABSTRACT SEVERAL CURRENTLY ADMINISTERED ANTIBIOTICS RAISE TWO MAIN CONCERNS: RESISTANCE AND NON-SELECTIVITY. THE RAPID RATE OF EMERGING MULTI-DRUG RESISTANCE POSES A GLOBAL HEALTH THREAT AND DRAMATICALLY INCREASES ECONOMIC BURDEN. WITH TRADITIONAL ANTIBIOTICS BEING LARGELY NON-SELECTIVE, THERE ARE SERIOUS SIDE EFFECTS DUE TO THE NATURAL HOST MICROBIOME BEING MODIFIED, AND THUS A LOSS IN HOMEOSTASIS. THE STRONG NEED FOR INNOVATIVE, POTENT, NATURALLY OCCURRING AND SPECIFICALLY SELECTIVE THERAPEUTICS HAVE PROMPTED US TO EXPLORE FOR SUCH BIOACTIVE MOLECULES IN MILK. THE RESULT OF 200 MILLION YEARS OF EVOLUTIONARY PRESSURE, MAMMALIAN LACTATION GUIDES THE DEVELOPMENT OF THE INFANT AND PROVIDES PROTECTION FROM A WIDE-VARIETY OF INFECTIONS. UPON FRACTIONATING THOUSANDS OF NATURALLY OCCURRING PEPTIDES FROM HUMAN MILK, AND DISCOVERING THEIR ANTIBACTERIAL ACTIVITY, WE HAVE FOCUSED ON THE FUNCTION AND MECHANISM OF ACTION OF NOVEL ANTIMICROBIAL PEPTIDES FROM HUMAN MILK. ONE SUCH PEPTIDE, HBCA2, AN INTERNAL 12-MER SEQUENCE OF HUMAN B-CASEIN RAPIDLY ELIMINATES THE VIABILITY OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA, INCLUDING BUT NOT LIMITED TO CATEGORY 1 PRIORITY PATHOGENS. WE HAVE MADE THE KEY OBSERVATION THAT GARDNERELLA VAGINALIS, A MAJOR BACTERIAL VAGINOSIS (BV)-ASSOCIATED PATHOGEN, IS SUSCEPTIBLE TO HBCA2, WHEREAS THE VIABILITY OF KEY LACTOBACILLI LINKED TO A HEALTHY VAGINAL MICROBIOME REMAINS UNALTERED. BV REMAINS AN UNMET NEED, WITH FEW TREATMENT OPTIONS AND HIGH RATES OF RECURRENCE RESULTING IN SEVERAL PUBLIC HEALTH CONCERNS FOR WOMEN OF REPRODUCTIVE AGE. IT IS ASSOCIATED WITH OUTCOMES INCLUDING TO NOT LIMITED TO PRE-TERM LABOR, STI AND HIV TRANSMISSIONS, AND OTHER REPRODUCTIVE CHALLENGES. WE PROPOSE HBCA2, A MILK-BORNE, ANTIMICROBIAL PEPTIDE, WITH ITS UNIQUE SELECTIVITY FEATURE OF INERTNESS TOWARDS COMMENSAL BACTERIA, AS A LEAD CANDIDATE MOLECULE IN TOPICAL APPLICATIONS FOR THE TREATMENT OF BV—A THERAPY THAT COULD IN TURN REDUCE THE BURDEN OF BV OUTCOMES. IN THIS PHASE I SBIR GRANT, WE WILL EVALUATE A LARGER RANGE OF G. VAGINALIS STRAINS OTHER BACTERIAL VAGINOSIS ASSOCIATED BACTERIA AS WELL AS A LARGER NUMBER OF VAGINAL AND PROBIOTIC LACTOBACILLI FOR THEIR RESPONSE TO HBCA2 AND VARIANTS OF HBCA2 SYNTHESIZED TO ENHANCE EFFICACY. ADDITIONALLY, WE WILL DETERMINE THE HBCA2 MECHANISM OF ACTION, EXAMINE ITS EFFICACY AND/OR SYNERGY TO TRADITIONAL ANTIMICROBIALS, CHARACTERIZE RESISTANCE MUTATIONS (IF ANY), ANALYZE THE DIRECT EFFECT OF HBCA2 ON MAMMALIAN HOST CELLS AND DETERMINE THE IMPACT OF FUNCTION ON INFECTION AND INFLAMMATION IN PRE- CLINICAL INFECTION MODELS OF THE FEMALE REPRODUCTIVE TRACT. THIS WORK WILL AID THE PREPARATION FOR PHASE II, WHERE WE WILL TEST HBCA2 IN IN VIVO EFFICACY AND EARLY SAFETY PK STUDIES, AND DETERMINE CERVICOVAGINAL TISSUE IMPACT AND IMMUNE RESPONSE. ULTIMATELY, THIS PROPOSAL WILL ALLOW US TO FURTHER CHARACTERIZE HBCA2 ALONE OR IN COMBINATION WITH ADDITIONAL SUCH PEPTIDES AS POTENT ANTIBACTERIAL THERAPEUTIC, DERIVED FROM MILK, WHICH CAN BE EMPLOYED FOR TREATMENT OF RECURRENT BV VIA TOPICAL APPLICATIONS.
Department of Agriculture
$150K
RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS
Department of Agriculture
$100K
DOMESTIC WATER GRANTS - REGULAR
Department of Housing and Urban Development
$4,626
YOUTHBUILD
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Source: IRS e-Filed Form 990
No officer or director compensation data available for this organization.
This data is sourced from IRS Form 990, Part VII. It may not be available if the organization files Form 990-N (e-Postcard) or has not yet been enriched.
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
WarningTax-exempt status was revoked on May 15, 2022
Reinstated on May 15, 2022
Exemption type: 03
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2021 | $95.2K | — | $78.4K | $25.4K | — |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2021 | 990-EZ | Data | PDF not yet published by IRS |
Financial data: IRS Form 990 via ProPublica Nonprofit Explorer (Tax Year 2021)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File · ProPublica Nonprofit Explorer
Tax-deductibility: IRS Publication 78
Revocation status: IRS Auto-Revocation List